StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) company profile

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

About Gyre Therapeutics

Pharmaceutical Preparations, SIC 2834

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies targeting organ fibrosis and inflammatory conditions. The company's commercial portfolio includes ETUARY (pirfenidone) and Etorel (nintedanib) for idiopathic pulmonary fibrosis and other interstitial lung disorders, as well as Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its clinical pipeline features Hydronidone for liver fibrosis, along with candidates addressing acute liver failure, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. Gyre supplies therapies to adult patients requiring specialized pulmonary, hepatologic, and hospital-based medical care.

The company maintains corporate headquarters in San Diego, California, and conducts operations across the United States and the People's Republic of China. Commercial operations and clinical development in China run through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd., which oversees clinical research across numerous domestic medical centers and partners with local contract manufacturers.

Summary of the business section of Gyre Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Gyre Therapeutics, Inc.
Headquarters
San Diego, CA
Address
12730 High Bluff Drive, Suite 250 92130
Phone
(858) 284-0115
Website
gyretx.com
Employees
618, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Grant Thornton Zhitong Certified Public Accountants LLP, Beijing, China

Stock & identifiers

Ticker
GYRE
Former tickers
CBIO until Oct 30, 2023; TRGT until Oct 23, 2015
Exchange
Nasdaq
IPO date
Apr 12, 2006
Shares outstanding
112M, Aug 1, 2026
Public float
$72.60M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Oct 31, 2023; 1-for-15 reverse, Feb 13, 2017; 1-for-92 reverse, Nov 5, 2015; 1-for-7 reverse, Aug 21, 2015
SEC CIK
1124105
CUSIP
403783103
ISIN
US4037831033
FIGI
BBG000F88SY8
Share class FIGI
BBG001SDL5X7
LEI
549300TE6BBPJ0S88K48
EIN
56-2020050

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ying LuoChief Executive Officer, Director2,565,226
Songjiang MaPresident, Director2,806,084
Weiguo YeChief Operating Officer700,000
Joshua Benjamin BergmannGC and Corporate Secretary–
Jialiang (NMN) WangEVP, General Manager–
Yue XiongChief Scientific Officer–
Thomas Wilson EastlingChief Financial Officer15,000
Ruoyu ChenChief Financial Officer–
Maxwell KirkbyDirector–
Claire WestonDirector–
Renate ParryDirector–
Rodney L. NussbaumDirector–
Dan WengDirector–
Ping ZhangDirector–
Gordon CarmichaelDirector–
David M. EpsteinDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Han Ying Ph D
$353.32K-$1.14M$2.65M$89–
FY2025
Ping Zhang
$4.10M$2.89M$2.65M$89–
FY2024
Charles Wu Ph D
$15.35K$15.35K$491.57K$134–
FY2024
Han Ying Ph D
$2.89M$3.67M$491.57K$134–
FY2023
Charles Wu Ph D
$106.15K$1.18M$241.39K$398–
FY2023
Songjiang Ma
$103.03K$28.85M$241.39K$398–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Ping Zhang
Interim Chief Executive Officer
$189.78K$3.80M$100.00K$11.25K$4.10M–
Ruoyu Chen
Chief Financial Officer
$250.00K–$25.00K$10.58K$285.58K-56%
Weiguo Ye
Chief Operating Officer
$196.95K$4.46M$344.40K$22.07K$5.02M+1410%
Han Ying
Senior Vice President, Science and Former Chief Executive Officer
$309.02K–$35.00K$9.30K$353.32K-88%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 12, 2006
Securities offered
5,000,000
Exchange
Nasdaq
First trading day
Apr 12, 2006
First-day close
$8.66
Lock-up ends (est.)
Oct 9, 2006

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 618 total employees, including 172 employees in Beijing, 43 employees in Cangzhou and 403 employees in other regions, which were primarily our sales and marketing employees located across the nation.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 4, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 26, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 12, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 2, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 30, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 27, 2023Name changeName changed from CATALYST BIOSCIENCES, INC. to Gyre Therapeutics, Inc.
Jul 20, 2023Merger voteDefinitive merger proxy statement
May 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 2, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 27, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 23, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 18, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 2, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 4, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 4, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 20, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 19, 2015Name changeName changed from TARGACEPT INC to CATALYST BIOSCIENCES, INC.
May 22, 2015MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 12, 2006IPOInitial public offering priced (424B4 prospectus)

See a number that looks wrong?